Program
endoxifen
Also written as “(Z)-endoxifen”, “Z-Endoxifen” and “Endoxifen”.
Its studies are mostly in Puberty, Precocious · Breast Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Atossa Therapeutics | 42 open or running | phase 2since Oct 16, 2020 | Oct 16, 2020 | Nov 2026phase 2 · NCT05607004 |
| Jina Pharmaceuticals | 10 open or running | phase 3since Mar 16, 2020 | Mar 16, 2020 | none ahead |
Also a collaborator on its studies: inclin-inc, novum-pharmaceutical-research-services and lambda-therapeutic-research-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 16, 2020First study: phase 3 study in Bipolar I DisorderNew to Jina PharmaceuticalsJina Pharmaceuticals · NCT04315792 · 124 enrolled · United States
- Oct 16, 2020Atossa Therapeutics's first study: phase 2 study in Mammographic Breast DensityNew to Atossa TherapeuticsAtossa Therapeutics · NCT04616430 · 90 enrolled · Sweden
- Sep 27, 2021Phase 2 study in Breast DensityAtossa Therapeutics · NCT05068388 · 240 enrolled · Sweden
- Oct 26, 2022Phase 2 study in Breast NeoplasmsAtossa Therapeutics · NCT05607004 · 87 enrolled · United States
- Oct 6, 2026Phase 2 study in Puberty, PrecociousAtossa Therapeutics · NCT07869732 · 6 planned · United States
Ahead
- Nov 2026Primary completion: phase 2 study in Breast NeoplasmsAtossa Therapeutics · NCT05607004
- Jun 2028Primary completion: phase 2 study in Puberty, PrecociousAtossa Therapeutics · NCT07869732
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07869732Puberty, Precocious · United States | 2 | Not yet recruiting | Atossa Therapeutics | Jun 2028 | 6 |
| NCT05607004Breast Neoplasms · United States | 2 | Active, not recruiting | Atossa Therapeutics | Nov 2026 | 87 |
| NCT05068388Breast Density · Sweden | 2 | Completed | Atossa Therapeutics | Jun 14, 2024 | 240 |
| NCT04616430Mammographic Breast Density · Sweden | 2 | Completed | Atossa Therapeutics | Sep 10, 2018 | 90 |
| NCT04315792Bipolar I Disorder · United States | 3 | Completed | Jina Pharmaceuticals | Jan 25, 2021 | 124 |
How it is read
Names in the registry
- “(Z)-endoxifen”, 2 entries
- “Z-Endoxifen”, 1 entry
- “Endoxifen”, 1 entry
- “Topical endoxifen”, 1 entry
Conditions, from the studies’ own filings
- Puberty, Precocious, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.